1. bookTom 59 (2021): Zeszyt 4 (December 2021)
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2501-062X
Pierwsze wydanie
30 Mar 2015
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
access type Otwarty dostęp

Evaluation of oxidative stress markers in hospitalized patients with moderate and severe COVID-19

Data publikacji: 20 Nov 2021
Tom & Zeszyt: Tom 59 (2021) - Zeszyt 4 (December 2021)
Zakres stron: 375 - 383
Otrzymano: 29 Mar 2021
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2501-062X
Pierwsze wydanie
30 Mar 2015
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
Abstract

Background. Clinical evidence suggests increased oxidative stress in COVID-19 patients and this worsened redox status could potentially contribute to the progression of the disease.

Objectives. To investigate the oxidative stress we have measured oxidative stress parameters, namely, PAT (total antioxidant power, iron reducing) and d-ROMs (plasma peroxides). Additionally we have investigated their correlation with the most frequently used clinical parameters CRP, LDH, and NLR in serum from moderate and severe COVID-19 patients hospitalized in a tertiary hospital.

Methods. PAT and d-ROMs were determined by analytical photometric metric method in serum from 50 hospitalized patients. For each of them, two samples were collected and analyzed immediately after collection seven days apart.

Results. All patients at admission had a much higher value for plasma peroxides and a significant correlation between oxidative stress parameters and CRP, LDH, and NLR. (p<0.05), except for OS index (OSI) vs CRP in the severe group. At discharge, plasma peroxides were reduced and OSI was improved in the moderate group.

Conclusion. We consider that using OSI at the beginning of COVID-19 disease presents a valuable starting point for the general assessment of oxidative stress and hence enabling a better triage of the patients in terms of disease severity.

Keywords

1. WORLD HEALTH ORGANIZATION. 2020. Naming the coronavirus disease (COVID-19) and the virus that causes it [Internet]. Geneva (Switzerland): WHO; 2020 [cited 2020 May 21]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Search in Google Scholar

2. XU Z., SHI L., WANG Y., ZHANG J., HUANG L., ZHANG C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Resp Med. 2020;8(4):420–22.10.1016/S2213-2600(20)30076-X Search in Google Scholar

3. WANG D., HU B., HU C., ZHU F., LIU X., ZHANG J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–69.10.1001/jama.2020.1585704288132031570 Search in Google Scholar

4. ZHENG F., LIAO C., FAN QH., CHEN HB., ZHAO XG., XIE ZG., et al. Clinical characteristics of coronavirus disease 2019 in Hubei, China. Curr Med Sci. 2020;40(2):275–80.10.1007/s11596-020-2172-6709506532207032 Search in Google Scholar

5. AVANOGLU GULER A., TOMBUL N., AYSERT YILDIZ P., SELÇUK ÖZGER H., HIZEL K., GULBAHAR O. The assessment of serum ACE activity in COVID-19 and its association with clinical features andseverity of the disease. Scand J Clin Lab Invest. 2021;21:1–6. Search in Google Scholar

6. RICHARDSON S., HIRSCH JS., NARASIMHAN M., CRAWFORD M., MCGINN T., DAVIDSON K., et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–59.10.1001/jama.2020.6775717762932320003 Search in Google Scholar

7. ZHENG Z., PENG F., XU B., ZHAO J., LIU H., PENG J., et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25.10.1016/j.jinf.2020.04.021717709832335169 Search in Google Scholar

8. FU L., WANG B., YUAN T., CHEN X., AO Y., FITZPATRICK T., et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80(6):656–65.10.1016/j.jinf.2020.03.041715141632283155 Search in Google Scholar

9. HARRISON AG., LIN T., WANG P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41(12):1100–15.10.1016/j.it.2020.10.004755677933132005 Search in Google Scholar

10. SEYED HOSSEINI E., RIAHI KASHANI N., NIKZAD H., AZADBAKHT J., HASSANI BAFRANI H., HADDAD KASHANI H. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020;551:1–9.10.1016/j.virol.2020.08.011751380233010669 Search in Google Scholar

11. MAIUOLO J., MOLLACE R., GLIOZZI M., MUSOLINO V., CARRESI C., PAONE S., SCICCHITANO M., et al. The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. Int J Mol Sci. 2020;21(23):9309.10.3390/ijms21239309773035233291346 Search in Google Scholar

12. CECCHINI R., CECCHINI AL. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med Hypotheses. 2020;143:110102.10.1016/j.mehy.2020.110102735749832721799 Search in Google Scholar

13. IDDIR M., BRITO A., DINGEO G., FERNANDEZ DEL CAMPO S., SAMOUDA H., LA FRANO MR., et al. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. Nutrients. 2020;12(6):1562.10.3390/nu12061562 Search in Google Scholar

14. SUHAIL S., ZAJAC J., FOSSUM C., LOWATER H., MCCRACKEN C., SEVERSON N., et al. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. The Protein Journal. 2020;39:644–56.10.1007/s10930-020-09935-8 Search in Google Scholar

15. MIRONOVA GD., BELOSLUDTSEVA NV., ANANYAN MA. Prospects for the use of regulators of oxidative stress in the comprehensive treatment of the novel Coronavirus Disease 2019 (COVID-19) and its complications. Eur Rev Med Pharmacol Sci. 2020;16:8585–91. Search in Google Scholar

16. BELTRAN-GARCIA J., OSCA-VERDEGAL R., PALLARDO FV., FERRERES J., RODRIGUEZ M., MULET S., et al. Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression. Antioxidants (Basel). 2020;9(10):936.10.3390/antiox9100936 Search in Google Scholar

17. DELGADO-ROCHE L., MESTA F. Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. Arch Med Res. 2020;51(5):384–87.10.1016/j.arcmed.2020.04.019 Search in Google Scholar

18. SCHWARZ KB. Oxidative stress during viral infection: a review. Free Radic Biol Med. 1996;21(5):641–9.10.1016/0891-5849(96)00131-1 Search in Google Scholar

19. ZAFAR PARACHA U., FATIMA K., ALQAHTANI M., CHAUDHARY A., ABUZENADAH A., DAMANHOURI G., et al. Oxidative stress and hepatitis C virus. Virol J. 2013;10:251.10.1186/1743-422X-10-251375157623923986 Search in Google Scholar

20. HOSAKOTE Y., LIU T., CASTRO SM., GAROFALO RP., CASOLA A. Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes. Am J Respir Cell Mol Biol. 2009;41(3):348–57.10.1165/rcmb.2008-0330OC274275419151318 Search in Google Scholar

21. KHOMICH OA., KOCHETKOV SN., BARTOSCH B., IVANOV AV. Redox Biology of Respiratory Viral Infections. Viruses. 2018;10(8):392.10.3390/v10080392611577630049972 Search in Google Scholar

22. CHECCONI P., DE ANGELIS M., MARCOCCI ME., FRATERNALE A., MAGNANI M., PALAMARA AT., et al. Redox-Modulating Agents in the Treatment of Viral Infections. Int J Mol Sci. 2020;21(11):4084.10.3390/ijms21114084731289832521619 Search in Google Scholar

23. CAMINI FC., DA SILVA CAETANO CC., ALMEIDA LT., DE BRITO MAGALHÃES CL. Implications of oxidative stress on viral pathogenesis. Arch Virol. 2017;162(4):907–17.10.1007/s00705-016-3187-y28039563 Search in Google Scholar

24. ALAMDARI DH., MOGHADDAM AB., AMINI S., KERAMATI MR., ZARMEHRI AM., ALAMDARI AH., et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 2020;885:173494.10.1016/j.ejphar.2020.173494744015932828741 Search in Google Scholar

25. ZHANG R., WANG X., NI L., DI X., MA B., NIU S., et al. COVID-19: Melatonin as potential adjuvant treatment. Life Sci. 2020;250:117583.10.1016/j.lfs.2020.117583710258332217117 Search in Google Scholar

26. CUADRADO A., PAJARES M., BENITO C., JIMENEZ-VILLEGAS J., ESCOLL M., FERNANDEZ-GINES., et al. Can activation of NRF2 be a strategy against COVID-19? Trends Pharmacol Sci. 2020; 41(9):598–610.10.1016/j.tips.2020.07.003735980832711925 Search in Google Scholar

27. DE LAS HERAS N., MARTÍN GIMÉNEZ VM., FERDER L., MANUCHA W., LAHERA V. Implications of Oxidative Stress and Potential Role of Mitochondrial Dysfunction in COVID-19: Therapeutic Effects of Vitamin D. Antioxidants (Basel). 2020;9(9):897.10.3390/antiox9090897755573132967329 Search in Google Scholar

28. CARRATELLI M., IORIO EL., BIANCHI L. Methods to measure the oxidative stress. ADI Magazine. 2006;4(10):405–14. Search in Google Scholar

29. ALBERTI A., BOLOGNINI L., MACCIANTELLI D., CARATELLI M. The radical cation of N,N-diethyl-paraphenylendiamine: A possible indicator of oxidative stress in biological samples. Res Chem Interm. 2000;26:253–67.10.1163/156856700X00769 Search in Google Scholar

30. GADOTTI AC., LIPINSKI AL., VASCONCELLOS FT., MARQUEZE LF., CUNHA EB., CAMPOS AC., et al. Susceptibility of the patients infected with Sars-Cov2 to oxidative stress and possible interplay with severity of the disease. Free Radic Biol Med. 2021;165:184–190.10.1016/j.freeradbiomed.2021.01.044784646033524532 Search in Google Scholar

31. MUHAMMAD Y., AMINU KANI Y., ILIYA S., BUNZA MUHAMMAD J., BINJI A., EL-FULATY AHMAD A., et al. Deficiency of antioxidants and increased oxidative stress in COVID-19 patients: A cross sectional comparative study in Jigawa, Northwestern Nigeria. SAGE Open Med. 2021;9:1–8.10.1177/2050312121991246787128233614035 Search in Google Scholar

32. PINCEMAIL J., CAVALIER E., CHARLIER C., CHERAMY-BIEN JP., BREVERS E., AUDREY COURTOIS A. Oxidative Stress Status in COVID-19 Patients Hospitalized in Intensive Care Unit for Severe Pneumonia. A Pilot Study. Antioxidants (Basel). 2021;10(2):257.10.3390/antiox10020257791460333562403 Search in Google Scholar

33. POLONIKOV A. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients. ACS Infect Dis. 2020;6(7):1558–62.10.1021/acsinfecdis.0c00288726307732463221 Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo